Open AccessMore Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
Author(s) -
Ida Robertsen,
Anders Åsberg,
Tone Granseth,
Nils Tore Vethe,
Fatemeh Akhlaghi,
Mwlod Ghareeb,
Espen Molden,
Morten Reier-Nilsen,
Hallvard Holdaas,
Karsten Midtvedt
Publication year - 2014
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000443225.66960.7e
Subject(s) - rosuvastatin , fluvastatin , everolimus , medicine , pravastatin , dyslipidemia , rosuvastatin calcium , urology , atorvastatin , pharmacology , simvastatin , endocrinology , cholesterol , diabetes mellitus
Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy with fluvastatin, pravastatin, or atorvastatin. These agents may not sufficiently lower lipid levels, and therefore, a more potent agent like rosuvastatin maybe needed.